These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 27247756)

  • 61. Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.
    Kittaka M; Yoshimoto T; Schlosser C; Rottapel R; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2020 Feb; 35(2):382-395. PubMed ID: 31613396
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New roles for B cell receptor associated kinases: when the B cell is not the target.
    Nguyen PH; Niesen E; Hallek M
    Leukemia; 2019 Mar; 33(3):576-587. PubMed ID: 30700840
    [TBL] [Abstract][Full Text] [Related]  

  • 63. An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
    Andorsky DJ; Kolibaba KS; Assouline S; Forero-Torres A; Jones V; Klein LM; Patel-Donnelly D; Smith M; Ye W; Shi W; Yasenchak CA; Sharman JP
    Br J Haematol; 2019 Jan; 184(2):215-222. PubMed ID: 30183069
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
    Burke JM; Shustov A; Essell J; Patel-Donnelly D; Yang J; Chen R; Ye W; Shi W; Assouline S; Sharman J
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):e327-e331. PubMed ID: 29934062
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.
    Elías EE; Almejún MB; Colado A; Cordini G; Vergara-Rubio M; Podaza E; Risnik D; Cabrejo M; Fernández-Grecco H; Bezares RF; Custidiano MDR; Sánchez-Ávalos JC; Vicente Á; Garate GM; Borge M; Giordano M; Gamberale R
    Haematologica; 2018 Oct; 103(10):e458-e461. PubMed ID: 29748439
    [No Abstract]   [Full Text] [Related]  

  • 66. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
    Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Syk inhibitors in clinical development for hematological malignancies.
    Liu D; Mamorska-Dyga A
    J Hematol Oncol; 2017 Jul; 10(1):145. PubMed ID: 28754125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib.
    Sharman J; Di Paolo J
    Ther Adv Hematol; 2016 Jun; 7(3):157-70. PubMed ID: 27247756
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
    Robak P; Robak T
    Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
    Jorda R; Krajčovičová S; Králová P; Soural M; Kryštof V
    Eur J Med Chem; 2020 Oct; 204():112636. PubMed ID: 32731189
    [TBL] [Abstract][Full Text] [Related]  

  • 71. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
    Ji TT; Chen QN; Tao SD; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
    N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.